1-[(3S)-Piperidin-3-yl]pyrrolidin-2-one hydrochloride, 1g

3-(5-Ethyl-1,2,4-oxadiazol-3-yl)benzoic acid, 95.0%, 5g

methyl 3-methyl-2-oxobutanoate, 95.0%, 1g

6-Bromo-3-methoxyisoquinoline, 98%, 100mg

1H-BENZIMIDAZOLE-1-CARBOXYLIC ACID, 4-(BROMOMETHYL)-6-CHLORO-, 1,1-DIMETHYLETHYL ESTER, 95%, 250mg

SPIRO[3.3]HEPTANE-2,2-DICARBOXYLIC ACID, 95%, 500mg

Fmoc-(R)-3-Amino-4-(2-fluoro-phenyl)-butyric acid, 97%, 1g

(S)-3-((tert-Butoxycarbonyl)amino)-3-(2-chlorophenyl)propanoic acid, 95.0%, 5g

1,3,5-Tris(bromomethyl)-2,4,6-triethylbenzene, 95.0%, 25g

Microliter syringe GASTIGHT® series 1700 Point type 2, 250 µl, 1725 RN, 1 piece

5-CHLORO-2-METHYL-1H-PYRROLO[2,3-C]PYRIDINE, 95.0%, 250mg

Poly(4-hydroxy-2,2,6,6-tetramethyl-1-piperidineethanol-alt-1,4-butanedioic acid), 95.0%, 5g

1-Chloro-2,6-dibromo-4-fluorobenzene, 97.0%, 1g